Specific iron chelators determine the route of ferritin degradation

Blood

Volumn 114, Issue 20, 2009, Pages 4546-4551

  De Domenico, Ivana ^a   Ward, Diane McVey ^a   Kaplan, Jerry ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; PROTEASOME; PROTEIN LC3B; UNCLASSIFIED DRUG; IRON CHELATING AGENT; SIDEROPHORE;

ARTICLE; AUTOPHAGY; CELL CULTURE; CELL STRAIN HEK293; CONTROLLED STUDY; CULTURE MEDIUM; CYTOSOL; HELA CELL; HUMAN; HUMAN CELL; LYSOSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PHYSIOLOGY;

AUTOPHAGY; CELLS, CULTURED; CYTOSOL; DEFEROXAMINE; FERRITINS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IRON CHELATING AGENTS; LYSOSOMES; PROTEASOME ENDOPEPTIDASE COMPLEX; SIDEROPHORES;

EID: 73349099034     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-224188     Document Type: Article

References (30)

1. Chasteen ND, Harrison PM. Mineralization in ferritin: an efficient means of iron storage. J Struct Biol. 1999;126(3):182-194.
2. Theil EC. Iron, ferritin, and nutrition. Annu Rev Nutr. 2004;24:327-343.
3. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol. 2006;2(8):406-414.
4. De Domenico I, Vaughn MB, Li L, et al. Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome. EMBO J. 2006;25(22):5396-5404.
5. Bridges KR. Ascorbic acid inhibits lysosomal autophagy of ferritin. J Biol Chem. 1987;262(30):14773-14778.
6. Kidane TZ, Sauble E, Linder MC. Release of iron from ferritin requires lysosomal activity. Am J Physiol Cell Physiol. 2006;291(3):C445-C455.
7. Hershko C, Link G, Konijn AM, Cabantchik ZI. Objectives and mechanism of iron chelation therapy. Ann N Y Acad Sci. 2005;1054:124-135.
8. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093.
9. Mizushima N, Klionsky DJ. Protein turnover via autophagy: implications for metabolism. Annu Rev Nutr. 2007;27:19-40.
10. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy. 2007;3(6):542-545.
11. Llados i Vallory EA, Girot R, Lenoir G, Payet M, Houze P, Bourdon R. Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children. Eur J Pediatr. 1989;148(6):503-506.
12. Bourdon S, Houze P, Bourdon R. Quantification of desferrioxamine in blood plasma by inductively coupled plasma atomic emission spectrometry. Clin Chem. 1987;33(1):132-134.
13. Porter JB. Deferoxamine pharmacokinetics. Semin Hematol. 2001;38(1):63-68.
14. Lloyd JB, Cable H, Rice-Evans C. Evidence that desferrioxamine cannot enter cells by passive diffusion. Biochem Pharmacol. 1991;41(9):1361-1363.
15. Damke H, Baba T, Warnock DE, Schmid SL. Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol. 1994;127(4):915-934.
16. Dice JF. Chaperone-mediated autophagy. Autophagy. 2007;3(4):295-299.
17. Eskelinen EL, Schmidt CK, Neu S, et al. Disturbed cholesterol traffic but normal proteolytic function in LAMP-1/LAMP-2 double-deficient fibroblasts. Mol Biol Cell. 2004;15(7):3132-3145.
18. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290(5497):1717-1721.
19. Cutler NS, Heitman J, Cardenas ME. TOR kinase homologs function in a signal transduction pathway that is conserved from yeast to mammals. Mol Cell Endocrinol. 1999;155(1):135-142.
20. Ollinger K, Roberg K. Nutrient deprivation of cultured rat hepatocytes increases the desferrioxamine-available iron pool and augments the sensitivity to hydrogen peroxide. J Biol Chem. 1997;272(38):23707-23711.
21. Larson JA, Howie HL, So M. Neisseria meningitidis accelerates ferritin degradation in host epithelial cells to yield an essential iron source. Mol Microbiol. 2004;53(3):807-820.
22. Mehlhase J, Sandig G, Pantopoulos K, Grune T. Oxidation-induced ferritin turnover in microglial cells: role of proteasome. Free Radic Biol Med. 2005;38(2):276-285.
23. Rudeck M, Volk T, Sitte N, Grune T. Ferritin oxidation in vitro: implication of iron release and degradation by the 20S proteasome. IUBMB Life. 2000;49(5):451-456.
24. Kwok JC, Richardson DR. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents. Mol Pharmacol. 2004;65(1):181-195.
25. Blommaart EF, Krause U, Schellens JP, Vreeling-Sindelarova H, Meijer AJ. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J Biochem. 1997;243(1):240-246.
26. Radisky DC, Kaplan J. Iron in cytosolic ferritin can be recycled through lysosomal degradation in human fibroblasts. Biochem J. 1998;336:201-205.
27. Dong XP, Cheng X, Mills E, et al. The type IV mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel. Nature. 2008;455(7215):992-996.
28. Soe-Lin S, Apte SS, Andriopoulos B Jr, et al. Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo. Proc Natl Acad Sci U S A. 2009;106(14):5960-5965.
29. Van Ho A, Ward DM, Kaplan J. Transition metal transport in yeast. Annu Rev Microbiol. 2002;56:237-261.
30. Sohn YS, Breuer W, Munnich A, Cabantchik ZI. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood. 2008;111(3):1690-1699.